文献速递妇产科病理

卵巢癌:至少五种具有不同组织学特征和分子遗传学的不同疾病

Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics.
PubMed 文献 · Hum Pathol · 2018-06-23

基于组织病理学和分子遗传学,卵巢癌分为五种主要类型:高级别浆液性(70%)、子宫内膜样(10%)、透明细胞(10%)、黏液性(3%)和低级别浆液性(<5%)癌,占病例95%以上,代表不同预后和治疗的不同疾病。本文综述了分子病理学进展,增进了对卵巢癌生物学的理解并涉及患者管理。

要点

  • 卵巢癌分为五种主要类型,各具不同组织学与分子遗传学特征。
  • 高级别浆液性癌中TP53突变几乎均存在(96%),BRCA缺失导致同源重组修复缺陷。
  • 子宫内膜样和透明细胞癌起源于卵巢子宫内膜异位症,ARID1A突变分别占30%和50%。

核心结论

  • 卵巢癌至少分为五种不同疾病,具有 distinct 组织学特征、分子遗传学、预后和治疗。
  • 分子病理学进展增进了对卵巢癌生物学的理解,并与患者管理相关。

研究设计与样本

  • 综述,基于组织病理学和分子遗传学总结卵巢癌分子病理学进展。

主要发现

  • 高级别浆液性癌占70%,子宫内膜样癌10%,透明细胞癌10%,黏液性癌3%,低级别浆液性癌<5%。
  • 高级别浆液性癌中TP53突变几乎均存在(96%),早期p53缺失后BRCA缺失导致同源重组修复缺陷,触发染色体不稳定和广泛的体细胞拷贝数改变。
  • 低级别浆液性癌可能代表浆液性 borderline 肿瘤进展,BRAF或KRAS突变发生在一半至三分之一的病例。
  • 黏液性癌中KRAS突变占43.6%,HER2过表达/扩增占18.8%。
  • 子宫内膜样癌和透明细胞癌起源于卵巢子宫内膜异位症;ARID1A突变在子宫内膜样癌占30%,透明细胞癌占50%;透明细胞癌中PTEN失活突变占8%,PIK3CA激活突变占33%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Based on histopathology and molecular genetics, ovarian carcinomas are divided into five main types: high-grade serous (70%), endometrioid (10%), clear cell (10%), mucinous (3%), and low-grade serous (<5%) carcinomas. These tumors, which account for over 95% of cases, represent distinct diseases with different prognoses and treatments. TP53 mutations are identified in almost all (96%) high-grade serous carcinomas (HGSCs). Early p53 loss followed by BRCA loss leads to deficiency in homologous recombination (DHR) repair, which in turn triggers chromosomal instability and widespread somatic copy number changes. An undetermined number of cases of HGSCs originate in the tubal fimbria; however, an origin from the ovarian surface epithelium cannot be totally excluded. Low-grade serous carcinomas (LGSCs) most likely represent progression of SBTs. BRAF or KRAS mutations occur in one-third to one-half of cases. Mucinous carcinomas (MCs) typically show benign-appearing, borderline, non-invasive and invasive components indicating tumor progression. KRAS mutations occur in 43.6% of cases and overexpression/amplification of HER2 in 18.8%. Endometrioid and clear cell carcinomas (EC and CCC) originate from ovarian endometriosis. Compared with their uterine counterparts, ECs have a similar frequency of β-catenin abnormalities but lower rate of microsatellite instability (MI) and PTEN alterations. ARID1A mutations occur in both ECs (30%) and CCCs (50%) and may be encountered in adjacent endometriosis. CCCs carry inactivating PTEN mutations and activating mutations in PIK3CA in 8% and 33% of cases, respectively. This review summarizes recent advances in the molecular pathology, which have greatly improved our understanding of the biology of ovarian carcinomas and are also relevant to patient management.

来源:Hum Pathol,查看原文。版权归原作者所有。

引用

  1. Prat J, D'Angelo E, Espinosa I, et al. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol. 2018. PMID: 29944973. doi:10.1016/j.humpath.2018.06.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。